Hederasaponin B - CAS:36284-77-2

您当前的位置：

Hederasaponin B (Synonyms:刺五加叶中)

目录号 : KM16406 CAS No. : 36284-77-2 纯度 : 98%

Data Sheet SDS 产品使用指南

Hederasaponin B 是从 Hedera helix 中分离的，具有针对肠道病毒 71 (EV71) 各种亚型的广谱抗病毒活性。

规格	价格	是否有货	数量
5mg		In-stock
10mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Lacto-N-fucopentaose I In-stock
Hederasaponin B In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Hederasaponin B, isolated from Hedera helix, has broad-spectrum antiviral activity against various subgenotypes of Enterovirus 71 (EV71).

体外研究

Viral Infection
Hederasaponin B (0.4-50 μg/mL; 48 h) exhibited antiviral activity against EV71 C3 (EC50=24.77 μg/mL) and EV71 C4a (EC50=41.77 μg/mL) in Vero cells, with a CC50 greater than 50 μg/mL.
Hederasaponin B (50 μg/mL; 48 h) strongly inhibits the expression of EV71 VP2 capsid protein in Vero cells infected with EV71 C3 or C4a subtypes.

Others
Hederasaponin B (0.1-100 μM; 30 min) did not exhibit hepatoprotective activity against CCl4 induced damage in HepG2 cells at concentrations up to 100 μM.

Western Blot Analysis

Cell Line:	African green monkey kidney (Vero) cells
Concentration:	50 μg/mL
Incubation Time:	48 hours
Result:	Dramatically decreased the expression levels of the 34 kDa EV71 VP2 capsid protein in both EV71 C3-infected and EV71 C4a-infected Vero cells.

Cell Viability Assay

Cell Line:	human HepG2 cells
Concentration:	0.1 μM, 100 μM (tested across the range 0.1-100 μM)
Incubation Time:	30 min (pre-incubation prior to 0.4% CCl4 exposure for 6 h)
Result:	Exhibited no hepatoprotective effect against CCl₄-induced injury across the entire tested concentration range. Did not improve cell viability when compared to the CCl₄-injured control.

体内研究

Oral administration of 150 mg/kg Hederasaponin B (150 mg/kg; oral; After a single dose, the substance undergoes extensive metabolism, mainly through the deglycosylation pathway (accounting for 52.46% of fecal metabolites), and a total of 47 metabolites were identified in feces, urine, and plasma.

Animal Model:

Sprague-Dawley (SD) (male; 200 g)

Dosage:

150 mg/kg

Administration:

p.o.; single dose

Result:

Tentatively identified a total of 47 metabolites in rat biological samples, with 42 detected in feces, 11 in urine, and 9 in plasma.
Observed that deglycosylation was the primary metabolic pathway, accounting for 52.46 % of all metabolites in fecal samples based on semi-quantitative chromatographic peak areas.
Detected four glycosylated metabolites with higher molecular weight than the parent compound, which accounted for 11.55 % of the metabolites in rat feces.
Detected the prototype compound in all three sample matrices (feces, urine, plasma).
Found that the aglycone metabolite oleanolic acid and the deglycosylation metabolite M33 were the most abundant metabolites in feces.
Determined that the fecal route was the main excretion route of hederasaponin B and its metabolites.

分子式

C₅₉H₉₆O₂₅

分子量

1205.38

CAS号

36284-77-2

中文名称

刺五加叶中

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

2-8°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (82.96 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8296 mL	4.1481 mL	8.2961 mL
5 mM	0.1659 mL	0.8296 mL	1.6592 mL
10 mM	0.0830 mL	0.4148 mL	0.8296 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.07 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.07 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO → 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.07 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。